Clair C, Meigs Diabftes, Rigotti NA. Cesssation Diabetes and smoking cessation rapid progression of Smmoking nephropathy has been observed more frequently in smokers with T2DM compared to non-smoking patients [ 56575859 ]. Insulin can become more effective at lowering blood sugar levels just eight weeks after you quit smoking. International Journal of Lower Extremity Wounds,

Diabetes and smoking cessation -

Jha P, Ramasundarahettige C, Landsman V, et al. N Engl J Med ; Pirie K, Peto R, Reeves GK, Green J, Beral V. The 21st century hazards of smoking and benefits of stopping: a prospective study of one million women in the UK.

Lancet ; Smoking and Diabetes [Accessed 4 October] Diabetes CDC [Internet]. It is estimated that 1 in 2 people born after in the UK will be diagnosed with some form of cancer during their lifetime and that more than one in four will die from the disease. This briefing lays out how ICBs can deliver on the prevention agenda through tackling smoking as part of fulfilling their purpose and objectives.

This briefing is designed for health professionals and commissioners, to provide clear advice and examples of good practice in relation to smoking and surgery. It is endorsed by the Royal College of Surgeons of England and Edinburgh, the Royal College of Physicians, The Royal College of Anaesthetists and the Centre for Perioperative Care.

Our website uses cookies to distinguish you from other users of our website. This helps us to provide you with a good experience when you browse our website and also allows us to improve our site. A cookie is a small file of letters and numbers that we store on your browser or the hard drive of your computer if you agree.

Cookies contain information that is transferred to your computer's hard drive. These are cookies that are required for the operation of our website. Cookies necessary for the operation of the site are stored on your computer automatically.

See strictly necessary cookies. These allow us to recognise and count the number of visitors and to see how visitors move around our website when they are using it. This helps us to improve the way our website works, for example, by ensuring that users are finding what they are looking for easily.

See analytical or performance cookies. These cookies record your visit to our website, the pages you have visited and the links you have followed. We will use this information to make our website more relevant to your interests. Cookies The ASH website uses cookies to improve our website.

No individual information is shared. Accept all Deny all. Resources All Resources Smoking and Diabetes Fact Sheet. What is diabetes?

Types of diabetes. There are several types of diabetes, but the main ones are two main types of diabetes: Type 1 diabetes develops when your body cannot make insulin. Prevalence of diabetes. How smoking contributes to developing Type 2 diabetes.

The effect of smoking on diabetes complications. Smoking and morbidity. Benefits of stopping smoking. For further information on quitting smoking see: ASH. Stopping smoking. March NHS advice and support on quitting.

External Reviewers. Emma Elvin, Senior Clinical Advisor, Diabetes UK. Diabetes UK Statistics Team. Related Fact Sheet.

ASH Aug ASH Jun Fact Sheet. Strictly necessary cookies These are cookies that are required for the operation of our website. Article PubMed Google Scholar. Wei M, Gaskill SP, Haffner SM, Stern MP.

Effects of diabetes and level of glycaemia on all-cause and cardiovascular mortality. The San Antonio Heart Study. Al-Delaimy WK, Manson JE, Solomon CG, Kawachi I, Stampfer MJ, Willett WC, Hu FB. Smoking and risk of coronary heart disease among women with type 2 diabetes mellitus.

Arch Intern Med. Chuahirun T, Simoni J, Hudson C, Seipel T, Khanna A, Harrist RB, Wesson DE. Cigarette smoking exacerbates and its cessation ameliorates renal injury in type 2 diabetes. Am J Med Sci. Qin R, Chen T, Lou Q, Yu D.

Excess risk of mortality and cardiovascular events associated with smoking among patients with diabetes: meta-analysis of observational prospective studies. Int J Cardiol. Pan A, Wang Y, Talaei M, Hu FB.

Relation of smoking with total mortality and cardiovascular events among patients with diabetes mellitus: a meta-analysis and systematic review.

Standard di cura del diabete mellito AMD-SID. Ford ES, Mokdad AH, Gregg EW. Trends in cigarette smoking among US adults with diabetes: findings from the Behavioral Risk Factor Surveillance System.

Prev Med. Stanton CA, Keith DR, Gaalema DE, Bunn JY, Doogan NJ, Redner R, Kurti AN, Roberts ME, Higgins ST. Trends in tobacco use among US adults with chronic health conditions: National Survey on Drug Use and Health — Kawakami N, Takatsuka N, Shimizu H, Ishibashi H.

Effects of smoking on the incidence of non-insulin-dependent diabetes mellitus. Replication and extensions in a Japanese cohort of male employees. Am J Epidemiol. Willi C, Bodenmann P, Ghali WA, Faris PD, Cornuz J. Active smoking and the risk of type 2 diabetes: a systematic review and meta-analysis.

Akter S, Okazaki H, Kuwahara K, et al. Smoking, smoking cessation, and the risk of type 2 diabetes among Japanese adults: Japan Epidemiology Collaboration on Occupational Health Study. PLoS ONE. Incidence and risk factors for type 2 diabetes mellitus in transitional Thailand: results from the Thai cohort study.

BMJ Open. Han SJ, Kim HJ, Kim DJ, Lee KW, Cho NH. Incidence and predictors of type 2 diabetes among Koreans: a year follow up of the Korean genome and epidemiology study.

Diabetes Res Clin Pract. Akter S, Goto A, Mizoue T. Smoking and the risk of type 2 diabetes in Japan: a systematic review and meta-analysis.

J Epidemiol. Aeschbacher S, Schoen T, Clair C, Schillinger P, Schönenberger S, Risch M, Risch L, Conen D. Association of smoking and nicotine dependence with pre-diabetes in young and healthy adults. Swiss Med Wkly. PubMed Google Scholar. Bucheli JR, Manshad A, Ehrhart MD, Camacho J, Burge MR.

Association of passive and active smoking with pre-diabetes risk in a predominantly Hispanic population. J Investig Med. Śliwińska-Mossoń M, Milnerowicz H. The impact of smoking on the development of diabetes and its complications.

Diabetes Vasc Dis Res. Sung YT, Hsiao CT, Chang IJ, Lin YC, Yueh CY. Smoking cessation carries a short-term rising risk for newly diagnosed diabetes mellitus independently of weight gain: a 6-year retrospective cohort study. J Diabetes Res.

Yeh HC, Duncan BB, Schmidt MI, Wang NY, Brancati FL. Smoking, smoking cessation, and risk for type 2 diabetes mellitus: a cohort study. Ann Intern Med. Oba S, Noda M, Waki K, Nanri A, Kato M, Takahashi Y, Poudel-Tandukar K, Matsushita Y, Inoue M, Mizoue T, Tsugane S.

Smoking cessation increases short-term risk of type 2 diabetes irrespective of weight gain: the Japan public health center-based prospective study. Luo JH, Rossouw J, Tong E, Giovino GA, Lee CC, Chen C, Ockene JK, Qi L, Margolis KL. Smoking and diabetes: does the increased risk ever go away?

Hu Y, Zong G, Liu G, Wang M, Rosner B, Pan A, Willett WC, Manson JE, Hu FB, Sun Q. Smoking cessation, weight change, type 2 diabetes, and mortality. N Engl J Med.

American Diabetes Association. Lifestyle management: standards of medical care in diabetes Cardiovascular disease and risk management. Rawshani A, Eliasson B, Svensson AM, Miftaraj M, McGuire DK, Sattar N, Rosengren A, Gudbjörnsdottir S.

Mortality and cardiovascular disease in type 1 and type 2 diabetes. GBD Tobacco Collaborators. Smoking prevalence and attributable disease burden in countries and territories, — a systematic analysis from the Global Burden of Disease Study Roth GA, Johnson C, Abajobir A, Abd-Allah F, Abera SF, Abyu G, Ahmed M, et al.

Global, regional, and national burden of cardiovascular diseases for 10 causes, to J Am Coll Cardiol. Rawshani A. Risk factors, mortality, and cardiovascular outcomes in patients with type 2 diabetes.

Wan EY, Fong DYT, Fung CSC, Yu EYT, Chin WY, Chan AKC, Lam CLK. Prediction of five-year all-cause mortality in Chinese patients with type 2 diabetes mellitus—a population-based retrospective cohort study. J Diabetes Complicat. Barengo NC, Teuschl Y, Moltchanov V, Laatikainen T, Jousilahti P, Tuomilehto J.

Coronary heart disease incidence and mortality and all-cause mortality among diabetic people according to their smoking behavior.

Tob Induc Dis. Harvey JN. Trends in the prevalence of diabetic nephropathy in type 1 and type 2 diabetes.

Curr Opin Nephrol Hypertens. Boner G, Cooper ME. Diabetic nephropathy. Diabetes Technol Ther. Su S, Wang W, Sun T, Ma F, Wang Y, Li J, Xu Z.

Int Urol Nephrol. Cignarelli M, Lamacchia O, Di Paolo S, Gesualdo L. Cigarette smoking and kidney dysfunction in diabetes mellitus. J Nephrol. Christiansen JS. Cigarette smoking and prevalence of microangiopathy in juvenile-onset insulin-dependent diabetes mellitus. Gerber PA, Locher R, Schmid B, Spinas GA, Lehmann R.

Smoking is associated with impaired long-term glucose metabolism in patients with type 1 diabetes mellitus. Nutr Metab Cardiovasc Dis. Scott LJ, Warram JH, Hanna LS, Laffel LM, Ryan L, Krolewski AS.

A nonlinear effect of hyperglycemia and current cigarette smoking are the major determinants of the onset of microalbuminuria in type 1 diabetes. Feodoroff M, Harjutsalo V, Forsblom C, Thorn L, Wadén J, Tolonen N, Lithovius R, Groop PH. Smoking and progression of diabetic nephropathy in patients with type 1 diabetes.

Acta Diabetol. De Cosmo S, Lamacchia O, Rauseo A, et al. Cigarette smoking is associated with low glomerular filtration rate in male patients with type 2 diabetes. Briganti EM, Branley P, Chadban SJ, Shaw JE, McNeil JJ, Welborn TA, Atkins RC.

Smoking is associated with renal impairment and proteinuria in the normal population: the AusDiab kidney study: Australian Diabetes, Obesity and Lifestyle Study.

Am J Kidney Dis. Ikeda Y, Suehiro T, Takamatsu K, et al. Effect of smoking on the prevalence of albuminuria in Japanese men with non-insulin-dependent diabetes mellitus. Chuahirun T, Wesson DE. Cigarette smoking predicts faster progression of type 2 established diabetic nephropathy despite ACE inhibition.

Chuahirun T, Khanna A, Kimball K, et al. Cigarette smoking and increased urine albumin excretion are interrelated predictors of nephropathy progression in type 2 diabetes. Phisitkul K, Hegazy K, Chuahirun T, Hudson C, Simoni J, Rajab H, Wesson DE.

Continued smoking exacerbates but cessation ameliorates progression of early type 2 diabetic nephropathy. Hsu CC, Hwuang SJ, Chen T, Huang MC, Shin SJ, Wen CP, Shih YT, Yang HJ, Chang CT, Chang CJ, Loh CH, Fuh MT, Li YS, Chang HY.

Cigarette smoking and proteinuria in Taiwanese men with type 2 diabetes mellitus. Diabet Med. Kar D, Gillies C, Nath M, Khunti K, Davies MJ, Seidu S. Association of smoking and cardiometabolic parameters with albuminuria in people with type 2 diabetes mellitus: a systematic review and meta-analysis.

Chaturvedi NSJ, Fuller JH. The relationship between smoking and microvascular complications in the EURODIAB IDDM complications study. Gaedt Thorlund M, Borg Madsen M, Green A, Sjølie AK, Grauslund J. Is smoking a risk factor for proliferative diabetic retinopathy in type 1 diabetes.

Stratton IM, Kohner EM, Aldington SJ, Turner RC, Holman RR, Manley SE, Matthews DR. UKPDS risk factors for incidence and progression of retinopathy in type II diabetes over 6 years from diagnosis. Yan ZP, Ma JX. Risk factors for diabetic retinopathy in northern Chinese patients with type 2 diabetes mellitus.

Int J Ophthalmol. PubMed PubMed Central Google Scholar. Moss SE, Klein R, Klein BE. Association of cigarette smoking with diabetic retinopathy. Cigarette smoking and ten-year progression of diabetic retinopathy.

Yun JS, Lim TS, Cha SA, Ahn YB, Song KH, Choi JA, Kwon J, Jee D, Cho YK, Park YM, Ko SH. Clinical course and risk factors of diabetic retinopathy in patients with type 2 diabetes mellitus in Korea.

Diabetes Metab J. Guillausseau PJ, Massin P, Charles MA, Allaguy H, Guvenli Z, Virally M, Tielmans D, Assayag M, Warnet A, Lubetzki J. Glycaemic control and development of retinopathy in type 2 diabetes mellitus: a longitudinal study.

Cai X, Chen Y, Yang W, Gao X, Han X, Ji L. The association of smoking and risk of diabetic retinopathy in patients with type 1 and type 2 diabetes: a meta-analysis. Tesfaye S, Chaturvedi N, Eaton SE, et al. Vascular risk factors and diabetic neuropathy. Clair C, Cohen MJ, Eichler F, Selby KJ, Rigotti NA.

The effect of cigarette smoking on diabetic peripheral neuropathy: a systematic review and meta-analysis. J Gen Intern Med. Dros J, Wewerinke A, Bindels PJ, van Weert HC.

Accuracy of monofilament testing to diagnose peripheral neuropathy: a systematic review. Ann Fam Med. Ahmad A, Moinuddin A, Ahsan A, Goel A. Study of electrophysiological changes in sensory nerves among diabetic smokers.

J Clin Diagn Res. Anan F, Takahashi N, Shinohara T, Nakagawa M, Masaki T, Katsuragi I, Tanaka K, Kakuma T, Yonemochi H, Eshima N, Saikawa T, Yoshimatsu H. Smoking is associated with insulin resistance and cardiovascular autonomic dysfunction in type 2 diabetic patients.

Eur J Clin Investig. Article CAS Google Scholar. Bush T, Lovejoy JC, Deprey M, Carpenter KM. The effect of tobacco cessation on weight gain, obesity and diabetes risk.

Lino K, Iwase M, Tsutsu N, Iida M. Smoking cessation and glycaemic control in type 2 diabetic patients. Diabetes Obes Metab.

Taylor AE, Davies NM, Munafo MR. Smoking and diabetes: strengthening causal inference. Lycett D, Nichols L, Ryan R, Farley A, Roalfe A, Mohammed MA, Szatkowski L, Coleman T, Morris R, Farmer A, Aveyard P. The association between smoking cessation and glycaemic control in patients with type 2 diabetes: a THIN database cohort study.

Kaizu S, Kishimoto H, Iwase M, Fujii H, Ohkuma T, Ide H, Jodai T, Kikuchi Y, Idewaki Y, Hirakawa Y, Nakamura U, Kitazono T. Impact of leisure- time physical activity on glycemic control and cardiovascular risk factors in Japanese patients with type 2 diabetes mellitus: the Fukuoka diabetes registry.

Nilsson PM, Gudbjornsdottir S, Eliasson B, Cederholm J, Steering Committee of the Swedish National Diabetes Register. Smoking is associated with increased HbA1c values and microalbuminuria in patients with diabetes: data from the National Diabetes Register in Sweden.

Diabetes Metab. Targher G, Alberiche M, Zenere MB, Bonadonna RC, Muggeo M, Bonora E. Cigarette smoking and insulin resistance in patients with noninsulin-dependent diabetes mellitus. J Clin Endocr Metab. CAS PubMed Google Scholar. Peng K, Chen G, Liu C, et al. Association between smoking and glycemic control in diabetic patients: results from the Risk Evaluation of cancers in Chinese diabetic Individuals: a longitudinal REACTION study.

J Diabetes. Su J, Qin Y, Shen C, Gao Y, Pan EC, Pan XQ, Tao R, Zhang YQ, Wu M. Zhonghua Liu Xing Bing Xue Za Zhi. Pirie K, Peto R, Reeves GK, Green J, Beral V, Million Women Study Collaborators. The 21st century hazards of smoking and benefits of stopping: a prospective study of one million women in the UK.

Jha P, Ramasundarahettige C, Landsman V, Rostron B, Thun M, Anderson RN, McAfee T, Peto R. Association of smoking cessation and weight change with cardiovascular disease among adults with and without diabetes.

Luo JH, Rossouw J, Margolis KL. Smoking cessation, weight change, and coronary heart disease among postmenopausal women with and without diabetes. Blomster JI, Woodward M, Zoungas S, Hillis GS, Harrap S, Neal B, Poulter N, Mancia G, Chalmers J, Huxley R.

The harms of smoking and benefits of smoking cessation in women compared with men with type 2 diabetes: an observational analysis of the ADVANCE Action in Diabetes and Vascular Disease: preterax and diamicron modified release Controlled Evaluation trial. Luque-Ramírez M, Sanz de Burgoa V, en nombre de los participantes del estudio DIABETES.

Impact of smoking cessation on estimated cardiovascular risk in Spanish type 2 diabetes mellitus patients: the DIABETES study. Rev Clin Esp. Professional Practice Committee. Standards of medical care in diabetes— Caponnetto P, Russo C, Polosa R. Smoking cessation: present status and future perspectives.

Curr Opin Pharmacol. Polosa R, Benowitz NL. Treatment of nicotine addiction: present therapeutic options and pipeline developments. Trends Pharmacol Sci.

Reid RD, Malcolm J, Wooding E, Geertsma A, Aitken D, Arbeau D, Blanchard C, Gagnier JA, Gupta A, Mullen KA, Oh P, Papadakis S, Tulloch H, LeBlanc AG, Wells GA, Pipe AL.

Prospective, cluster-randomized trial to implement the ottawa model for smoking cessation in diabetes education programs in Ontario, Canada. Diabetes UK Care Survey Results Nagrebetsky A, Brettell R, Roberts N, Farmer A.

Smoking cessation in adults with diabetes: a systematic review and meta-analysis of data from randomised controlled trials. Clair C, Meigs JB, Rigotti NA. Smoking behavior among US adults with diabetes or impaired fasting glucose. Am J Med. Fan AZ, Rock V, Zhang X, Li Y, Elam-Evans L, Balluz L.

Trends in cigarette smoking rates and quit attempts among adults with and without diagnosed diabetes, United States, — Prev Chronic Dis. Tobacco TC. A clinical practice guideline for treating tobacco use and dependence: update.

Am J Prev Med. Gross J, Stitzer ML. Nicotine replacement: ten-week effects on tobacco withdrawal symptoms. Stead LF, Perera R, Bullen C, Mant D, Hartmann-Boyce J, Cahill K, Lancaster T. Nicotine replacement therapy for smoking cessation.

Cochrane Database Syst Rev. Hajek P, West R, Foulds J, Nilsson F, Burrows S, Meadow A. Randomized comparative trial of nicotine polacrilex, a transdermal patch, nasal spray, and an inhaler. Tønnesen P, Mikkelsen KL. Smoking cessation with four nicotine replacement regimes in a lung clinic. Eur Respir J.

Bullen C, McRobbie H, Thornley S, Glover M, Lin R, Laugesen M. Effect of an electronic nicotine delivery device e cigarette on desire to smoke and withdrawal, user preferences and nicotine delivery: randomised cross-over trial.

Tob Control. Dawkins L, Kimber C, Puwanesarasa Y, Soar K. First-versus second-generation electronic cigarettes: predictors of choice and effects on urge to smoke and withdrawal symptoms. Caponnetto P, Campagna D, Cibella F, Morjaria JB, Caruso M, Russo C, Polosa R.

Efficiency and safety of an electronic cigarette ECLAT as tobacco cigarettes substitute: a prospective month randomized control design study. Bullen C, Howe C, Laugesen M, McRobbie H, Parag V, Williman J, Walker N. Electronic cigarettes for smoking cessation: a randomized controlled trial.

Hajek P, Phillips-Waller A, Przulj D, Pesola F, Myers Smith K, Bisal N, Li J, Parrott S, Sasieni P, Dawkins L, Ross L, Goniewicz M, Wu Q, McRobbie HJ. A randomized trial of E-cigarettes versus nicotine-replacement therapy. Walker N, Parag V, Verbiest M, et al. Nicotine patches used in combination with e-cigarettes with and without nicotine for smoking cessation: a pragmatic, randomised trial.

Lancet Respir Med. Benowitz NL, Gourlay SG. Cardiovascular toxicity of nicotine: implications for nicotine replacement therapy. Eliasson B, Taskinen MR, Smith U. Long-term use of nicotine gum is associated with hyperinsulinemia and insulin resistance.

Eliasson B. Cigarette smoking and diabetes. Prog Cardiovasc Dis. DaCosta A, Guy JM, Tardy B, Gonthier R, Denis L, Lamaud M, Cerisier A, Verneyre H.

The bad news is that none of the smoking cessation medications have been studied specifically in the diabetic population. Therefore, the literature does not suggest that any particular cessation medication has enhanced efficacy.

Patients with diabetes have been included as a subpopulation in many studies, however, and extrapolations regarding the usefulness of particular medications can be made. For example, medications that attenuate the special issues of weight management and depression in this population may be useful.

As mentioned earlier, patients with diabetes tend to suffer from depression more than those in the general population. Depression and other psychiatric conditions also contribute to a greater prevalence of smoking and increase the risk of relapse after cessation. However, SSRIs and tricyclic antidepressants currently are not recommended for first-line therapy and have not been studied specifically in diabetic patients for the purpose of smoking cessation.

One last medication deserves mention. Rimonabant is a promising new smoking cessation medication for this population because of its unique additional effect of causing weight loss.

It is the first of a new class of agents—selective cannabinoid receptor antagonists —that, among other activities, are believed to alter central action on lipid and glucose metabolism and nicotine dependence.

Although rimonabant had not received Food and Drug Administration FDA approval at the time of this writing,preliminary controlled trials revealed that 20 mg per day for 10 weeks with follow-up after 42 weeks induced a Results of another study are more encouraging for the weight loss action.

That trial revealed that weight loss at 1 year with the mg dose yielded a reduction of 6. Patients with diabetes who smoke may represent a population more resistant to standard smoking cessation techniques.

Therefore, treatment paradigms may need to be more aggressive. It is reasonable to hypothesize that smoking cessation products may be more effective when used in combination treatment for this patient population, although literature to confirm this point is lacking.

There are two types of combination treatment: combined use of nicotine replacement therapy products and use of the nicotine patch in combination with bupropion. Although both the nicotine patch and gum can be used separately with success, studies have shown that using the patch for consistent,long-term therapy with the gum for breakthrough cravings is more effective than either form alone.

For example, a review of four studies showed that either the hour or hour transdermal patch plus up to seven pieces of gum per day increased the cessation rates and decreased the amount of withdrawal experienced when compared to either product alone.

The nicotine patch plus bupropion also seems to be more effective than using the patch alone. In a study by Jorenby et al. In this study, the abstinence rate for combination therapy was significantly better than that for the nicotine patch alone.

Interestingly, there was no difference in efficacy between combination therapy and bupropion alone. However, both medications offer advantages for patients. The nicotine patch is a preferred method of nicotine delivery for some patients because of its easy administration, and bupropion delays and attenuates weight gain, as mentioned previously.

Finally, the recommended length of a complete treatment period for patients on combination therapy is 3—6 months. The importance of focusing on diabetic patients who smoke with individualized interventions cannot be overemphasized.

As mentioned earlier,these patients are at increased risk for mortality and for developing cardiovascular and microvascular complications. Furthermore, reducing blood pressure and cholesterol are nonglycemic ways of attenuating the cardiovascular complications of diabetes. This was suggested by sub-analyses of the U.

Prospective Diabetes Study and the Scandinavian Simvastatin Survival Study, which reduced blood pressure and cholesterol levels,respectively. Also, factors inherent with this patient population inhibit the chances of successfully quitting. Smokers with diabetes are more likely to report that their health is in worse condition and that they participate less in self-care management activities than their non-smoking counterparts.

For example,respondents with diabetes to a questionnaire by Solberg et al. They also engaged in less physical activity than their nonsmoking counterparts. Conversely, this group of patients were more likely to report that their health was poorer and that they often had feelings of being depressed.

Smoking cessation in the general population benefits economic, clinical,and humanistic outcomes. However, the literature has not focused on the potential long-term impact of smoking cessation in the diabetic population. Possible economic gains include money saved through having fewer overall health care costs.

Patients save money by not perpetuating the addiction. The humanistic impact includes a greater sense of control over one's own health. Clinical measures include the following potential outcomes: attenuation of depression, decreased blood pressure and triglyceride levels, and enhanced glycemic control.

Unfortunately, the literature is lacking for such well-constructed studies in the diabetic population. Additionally, smoking is a modifiable cardiovascular risk factor, cessation of which, along with reducing blood pressure and cholesterol levels, could result in a reduction of morbidity and mortality in this patient population.

In fact, focusing on the risk management parameters of cardiovascular disease may reduce morbidity and mortality more than tightening glycemic control, as suggested by the results of several recent studies. Identifying smokers and providing support for their smoking cessation attempts is clearly effective.

Creative methods, such as elevation of smoking status to that of a vital sign, have been devised to remind clinicians how important this is.

Identifying smokers in the diabetic population and providing them with counseling is even more crucial. However, clinician counseling of patients regarding smoking cessation is still less than optimal.

This important follow-up is best implemented in a group program that provides behavioral, cognitive, and pharmacological assistance. For clinicians who take care of diabetic patients, identifying and providing smoking cessation interventions should be of the highest priority in diabetes control.

Diabetes care providers should advise their patients who smoke to stop, and preferably this should be repeated annually. Although not all smokers may be ready to stop at a particular time, clinicians should provide brief counseling about the risks of smoking and benefits of quitting.

Regarding the Transtheoretical Model, patients who present in a certain stage could receive stage-matched interventions to move them into the next readiness stage. For those who are ready to quit, smoking cessation medication should be provided with specific follow-up care or referral to a cessation clinic.

Practical counseling on behavioral and cognitive techniques could be provided during follow-up care. Patients who attend smoking cessation clinics and receive cessation medications are most likely to quit smoking. Although no particular medication can be recommended as superior for the diabetic population, consideration of combination therapy is warranted, especially for patients who are heavy smokers with a history of multiple quit attempts.

Special issues during a cessation attempt in this population include attention to weight gain and development of depression. Tailoring of cessation medications and counseling for weight gain prevention and consideration of pharmacotherapy for depression may be needed.

Finally,clinicians should consider smoking cessation as equally important to blood pressure and cholesterol control as methods of attenuating cardiovascular complications of diabetes. In conclusion, patients with diabetes who smoke represent a population that could potentially benefit even more than their nondiabetic counterparts from cessation programs.

These smoking cessation programs should be implemented with a focus on specific cognitive, behavioral, and pharmacological therapies that control weight and prevent depression. The outcomes benefits have not been studied extensively in this population.

However, smokers with diabetes represent a clinical challenge and could benefit from creative and specific interventions for cessation. Justin Joseph Sherman, MCS, PharmD, is an assistant professor of pharmacy practice at the University of Louisiana at Monroe and conducts clinical pharmacy services at the VA Outpatient Clinic in Monroe, La.

Sign In or Create an Account. Search Dropdown Menu. header search search input Search input auto suggest. filter your search All Content All Journals Diabetes Spectrum. Advanced Search. User Tools Dropdown. Sign In. Skip Nav Destination Close navigation menu Article navigation.

Volume 18, Issue 4. Previous Article Next Article. Characteristics of Smoking Cessation Programs. Post-cessation Weight Gain and Depression. Smoking and Insulin Resistance.

Pharmacotherapy for Smoking Cessation. Combination Therapy for Smoking Cessation. Outcomes Measures for Patients With Diabetes After Smoking Cessation.

Diabetes is a Diabetes and smoking cessation cessztion health condition that affects how HbAc measurement body turns food into energy. Over Kidney bean Mexican recipes, that can cause cessatlon health problems, such as Diabetes and smoking cessation disease Diabtes, vision lossand kidney disease. We now know that smoking is one cause of type 2 diabetes. No matter what type of diabetes you have, smoking makes your diabetes harder to manage. If you have diabetes and you smoke, you are more likely to have serious health problems from diabetes, including: 3. If you have diabetes and you smoke, quitting smoking will benefit your health right away. People with diabetes who quit are better able to manage their blood sugar levels. Justin J. Sherman; Kidney bean Mexican recipes Impact nad Smoking smokibg Quitting Smoking smokiny Patients Coenzyme Q and fatigue Diabetes. Diabetes and smoking cessation Spectr 1 October ; 18 4 : — Although cigarette smoking is the leading avoidable cause of death in the United States, its specific effects on people with diabetes are even more intricate and profound. Macrovascular and microvascular complications ensue more quickly in smokers with diabetes, and risk of mortality increases.

Subscribe Table of contents. In Scollo, MM and Winstanley, MH [editors]. Tobacco in Australia: Facts and issues. Melbourne: Cancer Council Victoria; The hormone insulin is produced in the pancreas and helps the body use glucose for energy. Type 1 Diabetes and smoking cessation most often occurs in childhood or young adulthood though iDabetes can cessafion at any age and is the result of low cesation of or the inability to aand insulin.

People with type 1 diabetes need Diabeyes replacement for survival. Type 2 is the cessatiom common form cessatioj diabetes; it Meal ideas for team sports mostly in people aged 40 years and over and is marked by reduced or less effective insulin.

Smokng uncommon in childhood, it is Diabetes and smoking cessation increasingly recognised in that younger age group. An estimated 1. Data from the —12 Australian Health Survey, which included both measured Body recomposition success stories Diabetes and smoking cessation data found that Diabetss every four adults with diagnosed diabetes, there was one person who was undiagnosed.

There are currently no Australian national csssation that capture the prevalence of type 1 diabetes at all ages, dmoking data is Diabeyes for children.

According to the National insulin-treated Diabetes Register NDRjust over 6, children aged 0—14 had type 1 diabetes in Some population groups are at Long-lasting antimicrobial effectiveness higher risk for ad, notably Smokiing Australians, people born overseas, Kidney bean Mexican recipes those subject to the poorest socio-economic circumstances.

Aboriginal and Torres Strait Cessatiom adults were annd 4 times as likely to have diabetes compared with Kidney bean Mexican recipes Australians. Diagetes prevalence and death smokimg for the most disadvantaged groups in the Disbetes are Diwbetes twice as high as those in the most advantaged groups of cessaiton population.

Type 1 diabetes is an autoimmune disease cessztion usually develops in childhood or early adolescence. The exact vessation is unknown, Body composition and health it is smokinb Diabetes and smoking cessation result from interaction between genetic and environmental factors.

A Stimulant-free metabolism enhancement with type 1 diabetes requires cessatioon insulin replacement to survive, unless a successful Diabetea transplant occurs. Type 2 diabetes involves Green tea for stress relief between genetic components, cssation and lifestyle risk factors.

Type 2 diabetes is largely Diabefes through lifestyle changes. Type 2 smokig can be Quinoa energy balls with changes to diet and physical activity, oral glucose-lowering drugs, Herbal Pain Relief injectable Kidney bean Mexican recipes medications, insulin injections, or a combination of these methods.

Gestational diabetes is characterised by glucose intolerance that develops Diabstes pregnancy. The ecssation factors for gestational diabetes are similar to those for type 2 diabetes: cesation are at DDiabetes risk if they are of relatively advanced age Healthy energy drinks obese when pregnant.

Usually, gestational diabetes can be managed Mineral-rich alternatives lifestyle changes to cessqtion and exercise, but some ceasation may Diavetes treatment with insulin or other Diabetes and smoking cessation.

There is some evidence that depression can increase the risk Performance stack supplements developing type 2 ceesation and diabetes complications. It is thought that the increased risk of type 2 may be due to Kidney bean Mexican recipes stress levels and weight gain.

Poor foetal nutrition leading cesaation low birthweight ceesation gestational age may predispose some individuals to type 2 diabetes. If these individuals ssmoking exposed to Diabees risk factors such as obesity and physical inactivity the likelihood of cessaton type 2 diabetes becomes greater.

Smokint report highlights Non-addictive natural energizer reducing Weight loss and healthy aging use Djabetes be promoted as a key sjoking health strategy to prevent and control xnd increasing worldwide epidemic of diabetes.

about There is smokiny positive dose s,oking relationship between cigarette smoking and the cessztion of smoming. The Hydration for optimal digestion during exercise of smoking smooking also important, with smoking dose per 10 pack-years associated snd a an incidence of diabetes mellitus for black adults in the US.

Plausible biological mechanisms for this association include increased central obesity in smokers, increased inflammation and oxidative stress, 6 increased insulin resistance, altered insulin secretion and other impairments to pancreatic function noted in smokers.

However, in contrast to the research studies above, a few studies have found no association between smoking and the risk of diabetes, suggesting the mechanism by which smoking influences diabetes may be very complex. A US multi—ethnic cohort study of 5, participants found no independent association between tobacco use and type 2 diabetes.

There is also evidence that exposure to secondhand smoke is positively and independently associated with the risk of type 2 diabetes, from several observational studies conducted in the US, 2526 Germany 27 and Japan. As well as being life threatening in its own right, diabetes can also lead to a range of other serious health problems, including coronary heart disease, stroke, peripheral vascular disease, kidney disease, eye disease, and complications in pregnancy and childbirth.

Diabetic complications are often classified as macrovascular complications coronary artery disease, peripheral arterial disease and stroke and microvascular complications diabetic nephropathy, neuropathy, and retinopathy. There is a dose-dependent association between smoking and cardiovascular disease in individuals with type 1 diabetes.

There is also an increased risk of stroke among men who are current or former smokers. The hazards of smoking were similar between men and women except for major coronary events where there was some evidence of a stronger effect in women.

The longer the period of cessation, the greater the benefit. The coronary heart disease mortality risk for smokers with type 2 diabetes was higher compared with non-smoking diabetics.

The incidence of coronary heart disease was higher among current smokers compared with non—smoking diabetics.

Cessation provided a some benefits with former smokers having a lower risk of coronary heart disease compared with current smokers but a higher risk than non—smoking diabetics. A cross-sectional study of 10, men and 15, Chinese women with diabetes found current smokers also have increased risk for poor glycemic control.

There was a dose-response relationship between active smoking and the risk of poor glycemic control in men. Former smokers who quit smoking for less than 10 years remained at increased risk for poor glycemic control, with the risk declining after 10 years of smoking cessation to approximate that of non-smokers.

Retinopathy a form of eye disease is a common microvascular complication of diabetes. Obesity, hyperglycemia and tobacco use predicted the onset of retinopathy between 9 and 17 years after diagnosis of diabetes.

After 17 years, the number of diabetic patients with severe retinopathy was small. This study concluded that the negative association of smoking on glycemic control may be partially responsible for the adverse association of smoking on the risk of complications in type 1 diabetes including retinopathy.

Nephropathy is a common complication of diabetes that causes end stage renal disease. The disease progresses from normal albuminuria to presence of microalbuminuria traces of protein in the urinethen macroalbuminuria protein in the urineand finally renal insufficiency.

A meta-analysis of four prospective cohort, seven case-control, and eight cross-sectional studies found that smokers with type 2 diabetes had a significantly higher risk of having albuminuria compared with never smokers.

Smoking is also a risk factor for developing diabetic foot ulcers and has a negative effect on the healing process. Smoking can also increase the severity of diabetic peripheral neuropathy55 which can increase the risk of foot ulcers.

Smoking cessation is beneficial and appears to reduce the risk of diabetic foot amputation. There is systematic review evidence described previously in this chapter that confirms smoking increases the risk of developing type 2 diabetes.

There is also evidence that the risk of developing diabetes is elevated in ex—smokers for several years following smoking cessation and declines over time. A prospective study of middle-aged men and women found that adults who quit smoking experienced changes in their metabolic profile and had an increased risk for diabetes, at its highest 3 years after quitting, but still present 6 years after quitting.

The increased risk may be partly associated with weight gain and systemic inflammation. Further analysis showed that the risk of developing diabetes in the long term was decreased by smoking despite the elevated risk in recent quitters. This risk decreased over time, reaching a risk level equivalent to that of never smokers after 10 years of sustained smoking cessation.

Data from cohort studies in the US found that the risk of type 2 diabetes was higher among recent quitters 2 to 6 years since smoking cessation than among current smokers. The risk peaked 5 to 7 years after quitting and then gradually declined.

In this study, the short term increase in risk of type 2 diabetes was associated with weight gain, and the risk was not increased among quitters who did not gain weight. Some recent evidence suggests that among smokers with type 2 diabetes, smoking cessation can result in weight gain and a short-term worsening of some diabetic symptoms that may discourage smokers with diabetes from attempting to quit.

This change was unrelated to weight gain. Qualitative research with type 2 diabetic smokers found that satisfaction with current health status, lack of knowledge about type 2 diabetes and smoking, and misconceptions about cessation resulted in negative attitudes toward quitting.

The quitting process was challenging, dealing with smoking among peer groups, psychological addiction and post-cessation weight gain key factors complicating the quitting process.

This evidence underscores the need for smoking cessation to be accompanied by other strategies for diabetes prevention and early detection, as recommended in current clinical guidelines in the US and in Australia.

In conclusion, cigarette smoking produces insulin resistance and chronic inflammation, which can accelerate macrovascular and microvascular complications, including retinopathy, neuropathy and nephropathy. Many clinical and experimental studies have found significant associations between cigarette smoking and development of diabetes, impaired glycaemic control, and diabetic complications microvascular and macrovascular.

A different lifestyle of smokers, in contrast to that maintained by non-smokers, may also contribute to these effects.

The development of type 2 diabetes is yet another harmful consequence of cigarette smoking, and one that adds to the heightened risks of CVD; smoking cessation is crucial to facilitating glycaemic control and limiting development of complications.

For recent news items and research on this topic, click here. Last updated January Australian Institute of Health and Welfare. Diabetes: Australian facts Canberra: AIHW cat. CVD 40, Australian Institute for Health and Welfare. Web report, Cat.

no: CVD AIHW, Incidence of gestational diabetes in Australia. Canberra, Australia: AIHW Cat. CVD85, Diabetes compendium. Sliwinska-Mosson M and Milnerowicz H. The impact of smoking on the development of diabetes and its complications. Diabetes and Vascular Disease Research, ; 14 4 US Department of Health and Human Services.

The Health Consequences of Smoking: 50 Years of Progress. A Report of the Surgeon General. Atlanta, GA: U. Department of Health and Human Services, Centers for Disease Control and Prevention, National Center for Chronic Disease Prevention and Health Promotion, Office on Smoking and Health,

: Diabetes and smoking cessation

Six Ways Quitting Smoking Improves Your Diabetes and Overall Health	The bad news is that none of the smoking cessation medications have been studied specifically in the diabetic population. Therefore, the literature does not suggest that any particular cessation medication has enhanced efficacy. Patients with diabetes have been included as a subpopulation in many studies, however, and extrapolations regarding the usefulness of particular medications can be made. For example, medications that attenuate the special issues of weight management and depression in this population may be useful. As mentioned earlier, patients with diabetes tend to suffer from depression more than those in the general population. Depression and other psychiatric conditions also contribute to a greater prevalence of smoking and increase the risk of relapse after cessation. However, SSRIs and tricyclic antidepressants currently are not recommended for first-line therapy and have not been studied specifically in diabetic patients for the purpose of smoking cessation. One last medication deserves mention. Rimonabant is a promising new smoking cessation medication for this population because of its unique additional effect of causing weight loss. It is the first of a new class of agents—selective cannabinoid receptor antagonists —that, among other activities, are believed to alter central action on lipid and glucose metabolism and nicotine dependence. Although rimonabant had not received Food and Drug Administration FDA approval at the time of this writing,preliminary controlled trials revealed that 20 mg per day for 10 weeks with follow-up after 42 weeks induced a Results of another study are more encouraging for the weight loss action. That trial revealed that weight loss at 1 year with the mg dose yielded a reduction of 6. Patients with diabetes who smoke may represent a population more resistant to standard smoking cessation techniques. Therefore, treatment paradigms may need to be more aggressive. It is reasonable to hypothesize that smoking cessation products may be more effective when used in combination treatment for this patient population, although literature to confirm this point is lacking. There are two types of combination treatment: combined use of nicotine replacement therapy products and use of the nicotine patch in combination with bupropion. Although both the nicotine patch and gum can be used separately with success, studies have shown that using the patch for consistent,long-term therapy with the gum for breakthrough cravings is more effective than either form alone. For example, a review of four studies showed that either the hour or hour transdermal patch plus up to seven pieces of gum per day increased the cessation rates and decreased the amount of withdrawal experienced when compared to either product alone. The nicotine patch plus bupropion also seems to be more effective than using the patch alone. In a study by Jorenby et al. In this study, the abstinence rate for combination therapy was significantly better than that for the nicotine patch alone. Interestingly, there was no difference in efficacy between combination therapy and bupropion alone. However, both medications offer advantages for patients. The nicotine patch is a preferred method of nicotine delivery for some patients because of its easy administration, and bupropion delays and attenuates weight gain, as mentioned previously. Finally, the recommended length of a complete treatment period for patients on combination therapy is 3—6 months. The importance of focusing on diabetic patients who smoke with individualized interventions cannot be overemphasized. As mentioned earlier,these patients are at increased risk for mortality and for developing cardiovascular and microvascular complications. Furthermore, reducing blood pressure and cholesterol are nonglycemic ways of attenuating the cardiovascular complications of diabetes. This was suggested by sub-analyses of the U. Prospective Diabetes Study and the Scandinavian Simvastatin Survival Study, which reduced blood pressure and cholesterol levels,respectively. Also, factors inherent with this patient population inhibit the chances of successfully quitting. Smokers with diabetes are more likely to report that their health is in worse condition and that they participate less in self-care management activities than their non-smoking counterparts. For example,respondents with diabetes to a questionnaire by Solberg et al. They also engaged in less physical activity than their nonsmoking counterparts. Conversely, this group of patients were more likely to report that their health was poorer and that they often had feelings of being depressed. Smoking cessation in the general population benefits economic, clinical,and humanistic outcomes. However, the literature has not focused on the potential long-term impact of smoking cessation in the diabetic population. Possible economic gains include money saved through having fewer overall health care costs. Patients save money by not perpetuating the addiction. The humanistic impact includes a greater sense of control over one's own health. Clinical measures include the following potential outcomes: attenuation of depression, decreased blood pressure and triglyceride levels, and enhanced glycemic control. Unfortunately, the literature is lacking for such well-constructed studies in the diabetic population. Additionally, smoking is a modifiable cardiovascular risk factor, cessation of which, along with reducing blood pressure and cholesterol levels, could result in a reduction of morbidity and mortality in this patient population. In fact, focusing on the risk management parameters of cardiovascular disease may reduce morbidity and mortality more than tightening glycemic control, as suggested by the results of several recent studies. Identifying smokers and providing support for their smoking cessation attempts is clearly effective. Creative methods, such as elevation of smoking status to that of a vital sign, have been devised to remind clinicians how important this is. Identifying smokers in the diabetic population and providing them with counseling is even more crucial. However, clinician counseling of patients regarding smoking cessation is still less than optimal. This important follow-up is best implemented in a group program that provides behavioral, cognitive, and pharmacological assistance. For clinicians who take care of diabetic patients, identifying and providing smoking cessation interventions should be of the highest priority in diabetes control. Diabetes care providers should advise their patients who smoke to stop, and preferably this should be repeated annually. Although not all smokers may be ready to stop at a particular time, clinicians should provide brief counseling about the risks of smoking and benefits of quitting. Regarding the Transtheoretical Model, patients who present in a certain stage could receive stage-matched interventions to move them into the next readiness stage. For those who are ready to quit, smoking cessation medication should be provided with specific follow-up care or referral to a cessation clinic. Practical counseling on behavioral and cognitive techniques could be provided during follow-up care. Patients who attend smoking cessation clinics and receive cessation medications are most likely to quit smoking. Although no particular medication can be recommended as superior for the diabetic population, consideration of combination therapy is warranted, especially for patients who are heavy smokers with a history of multiple quit attempts. Special issues during a cessation attempt in this population include attention to weight gain and development of depression. Tailoring of cessation medications and counseling for weight gain prevention and consideration of pharmacotherapy for depression may be needed. Finally,clinicians should consider smoking cessation as equally important to blood pressure and cholesterol control as methods of attenuating cardiovascular complications of diabetes. In conclusion, patients with diabetes who smoke represent a population that could potentially benefit even more than their nondiabetic counterparts from cessation programs. These smoking cessation programs should be implemented with a focus on specific cognitive, behavioral, and pharmacological therapies that control weight and prevent depression. The outcomes benefits have not been studied extensively in this population. However, smokers with diabetes represent a clinical challenge and could benefit from creative and specific interventions for cessation. Justin Joseph Sherman, MCS, PharmD, is an assistant professor of pharmacy practice at the University of Louisiana at Monroe and conducts clinical pharmacy services at the VA Outpatient Clinic in Monroe, La. Sign In or Create an Account. Search Dropdown Menu. header search search input Search input auto suggest. filter your search All Content All Journals Diabetes Spectrum. Advanced Search. User Tools Dropdown. Sign In. Skip Nav Destination Close navigation menu Article navigation. Volume 18, Issue 4. Previous Article Next Article. Characteristics of Smoking Cessation Programs. Post-cessation Weight Gain and Depression. Smoking and Insulin Resistance. Pharmacotherapy for Smoking Cessation. Combination Therapy for Smoking Cessation. Outcomes Measures for Patients With Diabetes After Smoking Cessation. Practical Clinical Recommendations and Conclusions. Article Navigation. Feature Articles October 01 The Impact of Smoking and Quitting Smoking on Patients With Diabetes Justin J. Sherman, MCS, PharmD Justin J. Sherman, MCS, PharmD. This Site. Google Scholar. Address correspondence and requests for reprints to Justin J. Sherman, MS,PharmD, University of Louisiana at Monroe, College of Health Sciences, University Ave. Diabetes Spectr ;18 4 — Get Permissions. toolbar search Search Dropdown Menu. toolbar search search input Search input auto suggest. Table 1. View large. View Large. Table 2. Strategies for Smokers With Diabetes. Table 3. Strategies for Postcessation Weight Gain and Depression. Table 4. FDA-Approved Smoking Cessation Medications. Department of Health and Human Services: Healthy People Midcourse Review and Revisions. Diabetes Care. Ann Fam Med. Diabetes Res Clin Pract. Addict Behav. Am J Med. Diabetes Educ. N Engl J Med. Am J Public Health. The World Health Organization Multinational Study Group. Res Nurs Health. J Clin Endocrinol Metab. J Am Coll Cardiol. Ann Pharmacother. Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study. Health Values. Pharmacotherapy of smoking cessation. Arch Fam Med. Type 1 diabetes What it is and what causes it Diabetes UK [Accessed 29 September ] [Internet]. British Heart Foundation BHF. January Heart statistics publications BHF [Accessed 4 October ]. Heart and Circulatory Disease Statistics - Chapter 5 - Risk Factors [Accessed 4 October ]. Number of people with diabetes reaches 4. NICE National Diabetes Audit: Report 2 Complications and Mortality, [Accessed 28 September ] Document summary Evidence search [Internet]. Sun J, Wang Y, Zhang X, Zhu S, He H. Prevalence of peripheral neuropathy in patients with diabetes: A systematic review and meta-analysis. Prim Care Diabetes. Pan A, Wang Y, Talaei M, Hu FB, Wu T. Relation of active, passive, and quitting smoking with incident type 2 diabetes: a systematic review and meta-analysis. Lancet Diabetes Endocrinol ;— Adams JM. United States Public Health Service Office of the Surgeon General; National Center for Chronic Disease Prevention and Health Promotion US Office on Smoking and Health. Smoking Cessation: A Report of the Surgeon General. Washington DC : US Department of Health and Human Services; PMID: National Center for Chronic Disease Prevention and Health Promotion US Office on Smoking and Health. The Health Consequences of Smoking—50 Years of Progress: A Report of the Surgeon General. Atlanta GA : Centers for Disease Control and Prevention US ; Jiang N, Huang F, Zhang X. Smoking and the risk of diabetic nephropathy in patients with type 1 and type 2 diabetes: a meta-analysis of observational studies. Impact Journals, LLC; ; 8 54 Rodica PB, Boulton AJM, Feldman EL, Bril V et al. Diabetic Neuropathy: A position statement by the American Diabetes Association. Diabetes Care. Papanas N, Ziegler D. Risk factors and comorbidities in diabetic neuropathy: An update The Review of Diabetic Studies. Claire C, Cohen MJ, Eichler, F et al. The effect of cigarette smoking on diabetic peripheral neuropathy: A systematic review and meta-analysis. Journal of General Internal Medicine. Gaedt Thorlund M, Borg Madsen M, Green A, Sjølie AK, Grauslund J. Is smoking a risk factor for proliferative diabetic retinopathy in type 1 diabetes. Campagna, D. et al. Smoking and diabetes: dangerous liaisons and confusing relationships. Diabetol Metab Syndr ; 11, Stratton IM, Kohner EM, Aldington SJ, Turner RC, Holman RR, Manley SE, Matthews DR. UKPDS risk factors for incidence and progression of retinopathy in type II diabetes over 6 years from diagnosis. Yan ZP, Ma JX. Risk factors for diabetic retinopathy in northern Chinese patients with type 2 diabetes mellitus. Int J Ophthalmol. Yun JS, Lim TS, Cha SA, Ahn YB, Song KH, Choi JA, Kwon J, Jee D, Cho YK, Park YM, Ko SH. Clinical course and risk factors of diabetic retinopathy in patients with type 2 diabetes mellitus in Korea. Diabetes Metab J. Cai X, Chen Y, Yang W, Gao X, Han X, Ji L. The association of smoking and risk of diabetic retinopathy in patients with type 1 and type 2 diabetes: a meta-analysis. Qin R, Chen T, Lou Q et al. Excess risk of mortality and cardiovascular events associated with smoking among patients with diabetes: meta-analysis of observational prospective studies. International Journal of Cardiology. Yuan S, Xue H-L, Yu H-J, Huang Y, Tang B-W, Yang X-H, et al. Cigarette smoking as a risk factor for type 2 diabetes in women compared with men: a systematic review and meta-analysis of prospective cohort studies. J Public Health Oxf. National Institute for Health and Care Excellence. NHS Digital National Diabetes Audit - Report 1 Care Processes and Treatment Targets , Full Report. Hu Y, Zong G, Liu G, Wang M, Rosner B, Pan A, et al. Smoking Cessation, Weight Change, Type 2 Diabetes, and Mortality. New England Journal of Medicine. Jha P, Ramasundarahettige C, Landsman V, et al. N Engl J Med ; Pirie K, Peto R, Reeves GK, Green J, Beral V. The 21st century hazards of smoking and benefits of stopping: a prospective study of one million women in the UK. Lancet ; Smoking and Diabetes [Accessed 4 October] Diabetes CDC [Internet]. It is estimated that 1 in 2 people born after in the UK will be diagnosed with some form of cancer during their lifetime and that more than one in four will die from the disease. This briefing lays out how ICBs can deliver on the prevention agenda through tackling smoking as part of fulfilling their purpose and objectives.
Breadcrumb	Smoking cessatino Diabetes Diabetes and smoking cessation smokinf October] Diabetes CDC [Internet]. Depression and other psychiatric conditions also Diabetse to a greater prevalence of smoking cesssation increase the risk of relapse after cessation. Nutrient-rich meals Diabetes and smoking cessation share the following link with will be able to read this content:. The importance of focusing on diabetic patients who smoke with individualized interventions cannot be overemphasized. There is some evidence that depression can increase the risk of developing type 2 diabetes and diabetes complications. People with type 1 diabetes need insulin replacement for survival. Nelson KM, Boyko EJ, Koepsell T.
Post-cessation Weight Gain and Depression	National Center for Chronic Disease Prevention and Health Promotion US Office on Smoking and Health. The Health Consequences of Smoking—50 Years of Progress: A Report of the Surgeon General. Atlanta GA : Centers for Disease Control and Prevention US ; Jiang N, Huang F, Zhang X. Smoking and the risk of diabetic nephropathy in patients with type 1 and type 2 diabetes: a meta-analysis of observational studies. Impact Journals, LLC; ; 8 54 Rodica PB, Boulton AJM, Feldman EL, Bril V et al. Diabetic Neuropathy: A position statement by the American Diabetes Association. Diabetes Care. Papanas N, Ziegler D. Risk factors and comorbidities in diabetic neuropathy: An update The Review of Diabetic Studies. Claire C, Cohen MJ, Eichler, F et al. The effect of cigarette smoking on diabetic peripheral neuropathy: A systematic review and meta-analysis. Journal of General Internal Medicine. Gaedt Thorlund M, Borg Madsen M, Green A, Sjølie AK, Grauslund J. Is smoking a risk factor for proliferative diabetic retinopathy in type 1 diabetes. Campagna, D. et al. Smoking and diabetes: dangerous liaisons and confusing relationships. Diabetol Metab Syndr ; 11, Stratton IM, Kohner EM, Aldington SJ, Turner RC, Holman RR, Manley SE, Matthews DR. UKPDS risk factors for incidence and progression of retinopathy in type II diabetes over 6 years from diagnosis. Yan ZP, Ma JX. Risk factors for diabetic retinopathy in northern Chinese patients with type 2 diabetes mellitus. Int J Ophthalmol. Yun JS, Lim TS, Cha SA, Ahn YB, Song KH, Choi JA, Kwon J, Jee D, Cho YK, Park YM, Ko SH. Clinical course and risk factors of diabetic retinopathy in patients with type 2 diabetes mellitus in Korea. Diabetes Metab J. Cai X, Chen Y, Yang W, Gao X, Han X, Ji L. The association of smoking and risk of diabetic retinopathy in patients with type 1 and type 2 diabetes: a meta-analysis. Qin R, Chen T, Lou Q et al. Excess risk of mortality and cardiovascular events associated with smoking among patients with diabetes: meta-analysis of observational prospective studies. International Journal of Cardiology. Yuan S, Xue H-L, Yu H-J, Huang Y, Tang B-W, Yang X-H, et al. Cigarette smoking as a risk factor for type 2 diabetes in women compared with men: a systematic review and meta-analysis of prospective cohort studies. J Public Health Oxf. National Institute for Health and Care Excellence. NHS Digital National Diabetes Audit - Report 1 Care Processes and Treatment Targets , Full Report. Hu Y, Zong G, Liu G, Wang M, Rosner B, Pan A, et al. Smoking Cessation, Weight Change, Type 2 Diabetes, and Mortality. New England Journal of Medicine. Jha P, Ramasundarahettige C, Landsman V, et al. N Engl J Med ; The nicotine patch is a preferred method of nicotine delivery for some patients because of its easy administration, and bupropion delays and attenuates weight gain, as mentioned previously. Finally, the recommended length of a complete treatment period for patients on combination therapy is 3—6 months. The importance of focusing on diabetic patients who smoke with individualized interventions cannot be overemphasized. As mentioned earlier,these patients are at increased risk for mortality and for developing cardiovascular and microvascular complications. Furthermore, reducing blood pressure and cholesterol are nonglycemic ways of attenuating the cardiovascular complications of diabetes. This was suggested by sub-analyses of the U. Prospective Diabetes Study and the Scandinavian Simvastatin Survival Study, which reduced blood pressure and cholesterol levels,respectively. Also, factors inherent with this patient population inhibit the chances of successfully quitting. Smokers with diabetes are more likely to report that their health is in worse condition and that they participate less in self-care management activities than their non-smoking counterparts. For example,respondents with diabetes to a questionnaire by Solberg et al. They also engaged in less physical activity than their nonsmoking counterparts. Conversely, this group of patients were more likely to report that their health was poorer and that they often had feelings of being depressed. Smoking cessation in the general population benefits economic, clinical,and humanistic outcomes. However, the literature has not focused on the potential long-term impact of smoking cessation in the diabetic population. Possible economic gains include money saved through having fewer overall health care costs. Patients save money by not perpetuating the addiction. The humanistic impact includes a greater sense of control over one's own health. Clinical measures include the following potential outcomes: attenuation of depression, decreased blood pressure and triglyceride levels, and enhanced glycemic control. Unfortunately, the literature is lacking for such well-constructed studies in the diabetic population. Additionally, smoking is a modifiable cardiovascular risk factor, cessation of which, along with reducing blood pressure and cholesterol levels, could result in a reduction of morbidity and mortality in this patient population. In fact, focusing on the risk management parameters of cardiovascular disease may reduce morbidity and mortality more than tightening glycemic control, as suggested by the results of several recent studies. Identifying smokers and providing support for their smoking cessation attempts is clearly effective. Creative methods, such as elevation of smoking status to that of a vital sign, have been devised to remind clinicians how important this is. Identifying smokers in the diabetic population and providing them with counseling is even more crucial. However, clinician counseling of patients regarding smoking cessation is still less than optimal. This important follow-up is best implemented in a group program that provides behavioral, cognitive, and pharmacological assistance. For clinicians who take care of diabetic patients, identifying and providing smoking cessation interventions should be of the highest priority in diabetes control. Diabetes care providers should advise their patients who smoke to stop, and preferably this should be repeated annually. Although not all smokers may be ready to stop at a particular time, clinicians should provide brief counseling about the risks of smoking and benefits of quitting. Regarding the Transtheoretical Model, patients who present in a certain stage could receive stage-matched interventions to move them into the next readiness stage. For those who are ready to quit, smoking cessation medication should be provided with specific follow-up care or referral to a cessation clinic. Practical counseling on behavioral and cognitive techniques could be provided during follow-up care. Patients who attend smoking cessation clinics and receive cessation medications are most likely to quit smoking. Although no particular medication can be recommended as superior for the diabetic population, consideration of combination therapy is warranted, especially for patients who are heavy smokers with a history of multiple quit attempts. Special issues during a cessation attempt in this population include attention to weight gain and development of depression. Tailoring of cessation medications and counseling for weight gain prevention and consideration of pharmacotherapy for depression may be needed. Finally,clinicians should consider smoking cessation as equally important to blood pressure and cholesterol control as methods of attenuating cardiovascular complications of diabetes. In conclusion, patients with diabetes who smoke represent a population that could potentially benefit even more than their nondiabetic counterparts from cessation programs. These smoking cessation programs should be implemented with a focus on specific cognitive, behavioral, and pharmacological therapies that control weight and prevent depression. The outcomes benefits have not been studied extensively in this population. However, smokers with diabetes represent a clinical challenge and could benefit from creative and specific interventions for cessation. Justin Joseph Sherman, MCS, PharmD, is an assistant professor of pharmacy practice at the University of Louisiana at Monroe and conducts clinical pharmacy services at the VA Outpatient Clinic in Monroe, La. Sign In or Create an Account. Search Dropdown Menu. header search search input Search input auto suggest. filter your search All Content All Journals Diabetes Spectrum. Advanced Search. User Tools Dropdown. Sign In. Skip Nav Destination Close navigation menu Article navigation. Volume 18, Issue 4. Previous Article Next Article. Characteristics of Smoking Cessation Programs. Post-cessation Weight Gain and Depression. Smoking and Insulin Resistance. Pharmacotherapy for Smoking Cessation. Combination Therapy for Smoking Cessation. Outcomes Measures for Patients With Diabetes After Smoking Cessation. Practical Clinical Recommendations and Conclusions. Article Navigation. Feature Articles October 01 The Impact of Smoking and Quitting Smoking on Patients With Diabetes Justin J. Sherman, MCS, PharmD Justin J. Sherman, MCS, PharmD. This Site. Google Scholar. Address correspondence and requests for reprints to Justin J. Sherman, MS,PharmD, University of Louisiana at Monroe, College of Health Sciences, University Ave. Diabetes Spectr ;18 4 — Get Permissions. toolbar search Search Dropdown Menu. toolbar search search input Search input auto suggest. Table 1. View large. View Large. Table 2. Strategies for Smokers With Diabetes. Table 3. Strategies for Postcessation Weight Gain and Depression. Table 4. FDA-Approved Smoking Cessation Medications. Department of Health and Human Services: Healthy People Midcourse Review and Revisions. Sliwinska-Mosson M and Milnerowicz H. The impact of smoking on the development of diabetes and its complications. Diabetes and Vascular Disease Research, ; 14 4 US Department of Health and Human Services. The Health Consequences of Smoking: 50 Years of Progress. A Report of the Surgeon General. Atlanta, GA: U. Department of Health and Human Services, Centers for Disease Control and Prevention, National Center for Chronic Disease Prevention and Health Promotion, Office on Smoking and Health, Willi C, Bodenmann P, Ghali WA, Faris PD, and Cornuz J. Active smoking and the risk of type 2 diabetes: a systematic review and meta-analysis. JAMA, ; 22 Kawada T, Otsuka T, Inagaki H, Wakayama Y, Li Q, et al. Association of smoking status, insulin resistance, body mass index, and metabolic syndrome in workers: A 1-year follow-up study. Cho NH, Chan JC, Jang HC, Lim S, Kim HL, et al. Cigarette smoking is an independent risk factor for type 2 diabetes: a four-year community-based prospective study. Clinical Endocrinology, ; 71 5 Jee SH, Foong AW, Hur NW, and Samet JM. Smoking and risk for diabetes incidence and mortality in Korean men and women. Diabetes Care, ; 33 12 Xie XT, Liu Q, Wu J, and Wakui M. Impact of cigarette smoking in type 2 diabetes development. Acta Pharmacologica Sinica, ; 30 6 Maddatu J, Anderson-Baucum E, and Evans-Molina C. Smoking and the risk of type 2 diabetes. Translational Research, ; Chen C, Tu YQ, Yang P, Yu QL, Zhang S, et al. Assessing the impact of cigarette smoking on beta-cell function and risk for type 2 diabetes in a non-diabetic Chinese cohort. American Journal of Translational Research, ; 10 7 Kim JH, Seo DC, Kim BJ, Kang JG, Lee SJ, et al. Association between Cigarette Smoking and New-Onset Diabetes Mellitus in 78, Koreans Using Self-Reported Questionnaire and Urine Cotinine. Kim JH, Kim BJ, Kang JG, Kim BS, and Kang JH. Association between cigarette smoking and diabetes mellitus using two different smoking stratifications in Korean individuals: Self-reported questionnaire and urine cotinine concentrations. Journal of Diabetes, ; 11 3 Akter S, Okazaki H, Kuwahara K, Miyamoto T, Murakami T, et al. Smoking, Smoking Cessation, and the Risk of Type 2 Diabetes among Japanese Adults: Japan Epidemiology Collaboration on Occupational Health Study. PLoS ONE, ; 10 7 :e Akter S, Goto A, and Mizoue T. Smoking and the risk of type 2 diabetes in Japan: A systematic review and meta-analysis. Journal of Epidemiology, ; 27 12 Yuan S, Xue HL, Yu HJ, Huang Y, Tang BW, et al. Cigarette smoking as a risk factor for type 2 diabetes in women compared with men: a systematic review and meta-analysis of prospective cohort studies. Journal of Public Health, ; 41 2 :ee Pan A, Wang Y, Talaei M, Hu FB, and Wu T. Relation of active, passive, and quitting smoking with incident type 2 diabetes: a systematic review and meta-analysis. Lancet Diabetes and Endocrinology, ; 3 12 White WB, Cain LR, Benjamin EJ, DeFilippis AP, Blaha MJ, et al. High-Intensity Cigarette Smoking Is Associated With Incident Diabetes Mellitus In Black Adults: The Jackson Heart Study. Journal of the American Heart Association, ; 7 2. Yuan S and Larsson SC. A causal relationship between cigarette smoking and type 2 diabetes mellitus: A Mendelian randomization study. Science Reports ; 9 1 Ligthart S, Steenaard RV, Peters MJ, van Meurs JB, Sijbrands EJ, et al. Tobacco smoking is associated with DNA methylation of diabetes susceptibility genes. Diabetologia, ; 59 5 Keith RJ, Al Rifai M, Carruba C, De Jarnett N, McEvoy JW, et al. Tobacco Use, Insulin Resistance, and Risk of Type 2 Diabetes: Results from the Multi-Ethnic Study of Atherosclerosis. PLoS ONE, ; 11 6 :e Hou X, Qiu J, Chen P, Lu J, Ma X, et al. Cigarette Smoking Is Associated with a Lower Prevalence of Newly Diagnosed Diabetes Screened by OGTT than Non-Smoking in Chinese Men with Normal Weight. PLoS ONE, ; 11 3 :e Houston TK, Person SD, Pletcher MJ, Liu K, Iribarren C, et al. Active and passive smoking and development of glucose intolerance among young adults in a prospective cohort: CARDIA study. BMJ, ; Zhang L, Curhan GC, Hu FB, Rimm EB, and Forman JP. Association between passive and active smoking and incident type 2 diabetes in women. Diabetes Care, ; 34 4 Kowall B, Rathmann W, Strassburger K, Heier M, Holle R, et al. European Journal of Epidemiology, ; 25 6 Hayashino Y, Fukuhara S, Okamura T, Yamato H, Tanaka H, et al. A prospective study of passive smoking and risk of diabetes in a cohort of workers: the High-Risk and Population Strategy for Occupational Health Promotion HIPOP-OHP study. Diabetes Care, ; 31 4 Kim JH, Noh J, Choi JW, and Park EC. Association of Education and Smoking Status on Risk of Diabetes Mellitus: A Population-Based Nationwide Cross-Sectional Study. International Journal of Environmental Research and Public Health, ; 14 6. Jiang F, Wang J, Zhang R, Chen M, Peng D, et al. Effects of active and passive smoking on the development of cardiovascular disease as assessed by a carotid intima-media thickness examination in patients with type 2 diabetes mellitus. Clinical and Experimental Pharmacology and Physiology, ; 42 5 American Diabetes Association. Standards of medical care in diabetes Diabetes Care, ; 34 Suppl 1 Suppl 1 :S Díte P, Trna J, Belobrádková J, Novotný I, Hermanová M, et al. Vnitrni Lekarstvi, ; 57 2 Matsubayashi H, Maeda A, Kanemoto H, Uesaka K, Yamazaki K, et al. Risk factors of familial pancreatic cancer in Japan: current smoking and recent onset of diabetes. Pancreas, ; 40 6 Park SM, Lim MK, Jung KW, Shin SA, Yoo KY, et al. Prediagnosis smoking, obesity, insulin resistance, and second primary cancer risk in male cancer survivors: National Health Insurance Corporation Study. Journal of Clinical Oncology, ; 25 30

Video

Diabetes and Smoking